According to Teipel, whether someone is suitable for treatment or not must be considered individually. Treatment with lecanemab only makes sense in an early stage of Alzheimer’s disease. Those with advanced symptoms or another form of dementia would not benefit from treatment. In addition, the risk of side effects is particularly high in certain groups of people. “I would be more cautious about patients who take blood thinners and those who carry a double copy of the ApoE4 gene,” Teipel gives examples. The risk of cerebral hemorrhage is increased in these cases.
Questions and answers about lecanemab